Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models

Diabetologia

Volumn 55, Issue 5, 2012, Pages 1482-1494

  Kim, Y D ^a   Kim, Y H ^c   Cho, Y M ^a   Kim, D K ^a   Ahn, S W ^a   Lee, J M ^a   Chanda, D ^a   Shong, M ^d   Lee, C H ^c   Choi, H S ^a,b  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

AMP activated protein kinase; Insulin resistance; Insulin sensitivity; Interleukin 6; Metformin; Nr0b2; Shp; Small heterodimer partner

Indexed keywords

COREPRESSOR PROTEIN; HETERODIMER; INSULIN; INTERLEUKIN 6; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; ORPHAN NUCLEAR RECEPTOR; SCATTER FACTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GLUCONEOGENESIS; IMMUNOPRECIPITATION; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; TRANSACTIVATION; WILD TYPE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; METFORMIN; MICE; ORPHAN NUCLEAR RECEPTORS; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84862817442     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2494-4     Document Type: Article

References (35)

1. Tilg H, Moschen AR (2008) Insulin resistance, inflammation, and nonalcoholic fatty liver disease. Trends Endocrinol Metab 19: 371-379
2. Carter-Kent C, Zein NN, Feldstein AE (2008) Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103: 1036-1042
3. Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101: 10422-10427
4. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391-3399
5. Torisu T, Sato N, Yoshiga D et al (2007) The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12: 143-154
6. Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446
7. Holmes AG, Mesa JL, Neill BA et al (2008) Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPAR? and UCP2 expression in rats. J Endocrinol 198: 367-374
8. Sadagurski M, Norquay L, Farhang J, D'Aquino A, Copps K, White A (2010) Human IL-6 enhances leptin action in mice. Diabetologia 53: 525-535
9. Blumberg D, Hochwald S, Brennan MF, Burt M (1995) Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism 44: 145-146
10. Ritchie DG (1990) Interleukin-6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol 258: E57-E64
11. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82: 4167-4170
12. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptindeficient mice. Nat Med 6: 998-1003
13. Zhou G, Myers R, Li Yet al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174
14. Yuan L, Ziegler R, Hamann A (2003) Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated HepG2 cells. Acta Pharmacol Sin 24: 55-60
15. Kim YD, Park KG, Lee YS et al (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57: 306-314
16. Chanda D, Lee CH, Kim YH et al (2009) Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent nduction of orphan nuclear receptor small heterodimer partner. Hepatology 50: 880-892
17. Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9: 407-416
18. Lee YS, Chanda D, Sim J, Park YY, Choi HS (2007) Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 261: 117-158
19. Chanda D, Park JH, Choi HS (2008) Molecular basis of endocrine regulation by orphan nuclear receptor small heterodimer partner. Endocr J 55: 253-268
20. Um JH, Park SJ, Kang H et al (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563
21. Chanda D, Li T, Song KH et al (2009) Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem 284: 28510-28521
22. Chanda D, Kim SJ, Lee IK, Shong M, Choi HS (2008) Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression. Am J Physiol Endocrinol Metab 295: 368-379
23. Barclay JL, Anderson ST, Waters MJ, Curlewis JD (2007) Regulation of suppressor of cytokine signaling 3 (SOC3) by growth hormone in pro-B cells. Mol Endocrinol 21: 2503-2515
24. Gatto L, Berlato C, Poli V et al (2004) Analysis of SOCS-3 promoter responses to interferon gamma. J Biol Chem 279: 13746-13754
25. Shah M, Patel K, Fried VA, Sehgal PB (2002) Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem 277: 45662-45669
26. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789
27. Senn JJ, Klover PJ, Nowak IA et al (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740-13746
28. Wunderlich FT, Ströhle P, Könner AC et al (2010) Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 12: 237-249
29. Banzet S, Koulmann N, Simler N et al (2009) Control of gluconeogenic genes during intense/prolonged exercise: hormoneindependent effect of muscle-derived IL-6 on hepatic tissue and PEPCK mRNA. J Appl Physiol 107: 1830-1839
30. Stith RD, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44: 210-215
31. Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54: S114-S124
32. Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58: 1953-1960
33. Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688-2697
34. Nerstedt A, Johansson A, Andersson CX, Cansby E, Smith U, Mahlapuu M (2010) AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 53: 2406-2416
35. Sun H, Zhang Y, Gao P et al (2011) Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol Cell Biochem 347: 183-189